Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$22 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.5
Industry P/E
--
EV/EBITDA
-3.1
Div. Yield
0 %
Debt to Equity
0.7
Book Value
$--
EPS
$-0.8
Face value
--
Shares outstanding
59,252,900
CFO
$-189.58 Mln
EBITDA
$-189.99 Mln
Net Profit
$-195.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Elevation Oncology Inc (ELEV)
| -35.1 | -0.6 | -1.8 | -86.1 | -33.8 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Elevation Oncology Inc (ELEV)
| 4.7 | -43.5 | -84.2 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Elevation Oncology Inc (ELEV)
|
0.4 | 21.6 | 0.0 | -48.0 | -126,005.3 | -82.7 | -- | 0.5 |
| 8.7 | 544.9 | 70.4 | -301.2 | -431.1 | -72.2 | -- | 1.5 |
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug... conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a PD-1 inhibitor, and ramucirumab, a VEGFR2 inhibitor, in patients with advanced, unresectable, or metastatic gastric/gastroesophageal junction solid tumors. The company is also developing EO-1022, an ADC containing seribantumab, a fully human immunoglobulin G2 (IgG2) anti-HER3 mAb, and an MMAE payload, with glycan site-specific conjugation for the treatment of patients with HER3-expressing solid tumors, including breast cancer, non-small cell lung cancer, and other solid tumors. It has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021 for the treatment of cancer. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts. Read more
Chief Scientific Officer
Dr. David Dornan Ph.D.
Chief Scientific Officer
Dr. David Dornan Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Elevation Oncology Inc (ELEV) is $0.37 (NASDAQ) as of 01-Aug-2025 09:30 EDT. Elevation Oncology Inc (ELEV) has given a return of -33.83% in the last 3 years.
Since, TTM earnings of Elevation Oncology Inc (ELEV) is negative, P/E ratio is not available.
The P/B ratio of Elevation Oncology Inc (ELEV) is 0.46 times as on 01-Aug-2025, a 88 discount to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.75
|
0.55
|
|
2023
|
-0.50
|
0.42
|
|
2022
|
-0.23
|
0.45
|
|
2021
|
-2.28
|
0.52
|
|
2020
|
--
|
--
|
The 52-week high and low of Elevation Oncology Inc (ELEV) are Rs 2.68 and Rs 0.22 as of 05-Apr-2026.
Elevation Oncology Inc (ELEV) has a market capitalisation of $ 22 Mln as on 01-Aug-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Elevation Oncology Inc (ELEV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.